Interferon-alpha directly represses megakaryopoiesis by inhibiting thrombopoietin-induced signaling through induction of SOCS-1
- PMID: 10979953
Interferon-alpha directly represses megakaryopoiesis by inhibiting thrombopoietin-induced signaling through induction of SOCS-1
Abstract
Interferon (IFN)-alpha has proven useful for treating several clinical conditions, including chronic viral hepatitis and chronic myeloproliferative and lymphoproliferative disorders. In addition to its well-known antiviral effects, the cytokine exerts antiproliferative effects on many cell types, helping to explain its therapeutic usefulness in these latter conditions. However, this same property accounts for several undesirable effects, including thrombocytopenia, which can interfere with the successful clinical application of IFN-alpha. Unfortunately, the mechanisms responsible for the myelosuppressive effects of the cytokine are incompletely understood. The effects of IFN-alpha on megakaryocyte (MK) development were studied. Using several marrow cell purification techniques and quantitative culture methods, it was found that IFN-alpha directly inhibits thrombopoietin (TPO)-induced MK growth. Previous studies indicated that Janus kinase (JAK) and its substrates mediate the effects of TPO on cellular proliferation and survival. It was found that IFN-alpha directly suppresses TPO-induced phosphorylation of the JAK2 substrates c-Mpl and STAT 5 in a TPO-dependent hematopoietic cell line and of Mpl and STAT3 in primary murine MK. Moreover, IFN-alpha induces SOCS-1 production in these cells, which has been shown to inhibit TPO-induced cell growth. Because SOCS protein expression is induced by many cytokines and has been reported to extinguish signaling from several hematopoietic cytokine receptors, these results identify a molecular mechanism responsible for cytokine receptor cross-talk.
Similar articles
-
Thrombopoietin stimulates colony-forming unit-megakaryocyte proliferation and megakaryocyte maturation independently of cytokines that signal through the gp130 receptor subunit.Blood. 1996 Sep 15;88(6):2026-32. Blood. 1996. PMID: 8822921
-
[Interferon-alpha directly inhibits thrombopoietin-induced megakaryocyte proliferation and differentiation].Zhonghua Xue Ye Xue Za Zhi. 2001 Jun;22(6):296-9. Zhonghua Xue Ye Xue Za Zhi. 2001. PMID: 11877087 Chinese.
-
Thrombopoietin, but not cytokines binding to gp130 protein-coupled receptors, activates MAPKp42/44, AKT, and STAT proteins in normal human CD34+ cells, megakaryocytes, and platelets.Exp Hematol. 2002 Jul;30(7):751-60. doi: 10.1016/s0301-472x(02)00810-x. Exp Hematol. 2002. PMID: 12135673
-
Thrombopoietin: biology and clinical potentials.Int J Hematol. 1999 Dec;70(4):216-25. Int J Hematol. 1999. PMID: 10643146 Review.
-
[Thrombopoietin and megakaryocyte differentiation].Schweiz Med Wochenschr. 1998 Oct 17;128(42):1575-81. Schweiz Med Wochenschr. 1998. PMID: 9824885 Review. French.
Cited by
-
Incidence and predictors of hematological side effects in chronic HCV Egyptian patients treated with PEGylated interferon and ribavirin.Indian J Gastroenterol. 2013 Sep;32(5):316-23. doi: 10.1007/s12664-013-0336-z. Epub 2013 May 29. Indian J Gastroenterol. 2013. PMID: 23715642
-
STAT1 promotes megakaryopoiesis downstream of GATA-1 in mice.J Clin Invest. 2007 Dec;117(12):3890-9. doi: 10.1172/JCI33010. J Clin Invest. 2007. PMID: 18060035 Free PMC article.
-
Megakaryopoiesis impairment through acute innate immune signaling activation by azacitidine.J Exp Med. 2022 Nov 7;219(11):e20212228. doi: 10.1084/jem.20212228. Epub 2022 Sep 2. J Exp Med. 2022. PMID: 36053753 Free PMC article.
-
Developmental differences in IFN signaling affect GATA1s-induced megakaryocyte hyperproliferation.J Clin Invest. 2013 Jul 1;123(8):3292-304. doi: 10.1172/JCI40609. Online ahead of print. J Clin Invest. 2013. PMID: 23863621 Free PMC article.
-
The Rationale for Immunotherapy in Myeloproliferative Neoplasms.Curr Hematol Malig Rep. 2019 Aug;14(4):310-327. doi: 10.1007/s11899-019-00527-7. Curr Hematol Malig Rep. 2019. PMID: 31228096 Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous